코엡티스 테라퓨틱스(COEP)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.54 (+10.92%), 시가총액 $0.10B, 52주 최저~최고 $7.05 ~ $18.80.
As of April 24, 2026, Coeptis Therapeutics Holdings, Inc. was acquired by Z Squared Inc., in a reverse merger transaction. Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company's product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid
코엡티스 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
코엡티스 테라퓨틱스의 현재 주가는 $2.54 (+10.92%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
코엡티스 테라퓨틱스의 시가총액은 약 $0.10B입니다.
As of April 24, 2026, Coeptis Therapeutics Holdings, Inc. was acquired by Z Squared Inc., in a reverse merger transaction. Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates